ACM
TARO

Apex Capital Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Apex Capital Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$390K Buy
2,723
+938
+53% +$133K 0.01% 246
2015
Q4 		$276K Buy
+1,785
New +$261K 0.01% 238

Other funds holding TARO

Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Apex Capital Management's TARO Position: Q1 2016 in Review

Apex Capital Management increased its Taro Pharmaceutical Industries Ltd. (TARO) stake by 53% in Q1 2016, buying an estimated $133K and bringing the position to 2,723 shares worth $390K. The position accounts for 0.01% of the portfolio, ranked #246.

Apex Capital Management first reported a position in TARO in Q4 2015 and has held it in 2 quarters since. 167 funds tracked by Wall St. Rank hold TARO as of Q1 2016.

  • Apex Capital Management held 2,723 shares of Taro Pharmaceutical Industries Ltd. worth $390K as of Q1 2016.
  • Apex Capital Management bought 938 Taro Pharmaceutical Industries Ltd. shares in Q1 2016, an estimated $133K.
  • Taro Pharmaceutical Industries Ltd. made up 0.01% of Apex Capital Management's portfolio in Q1 2016, its #246 holding.
  • Apex Capital Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2015 and has held it in 2 quarters since.
  • 167 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.